The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 427-432

  Sun, Jong Mu ^a   Oh, Do Youn ^a,c   Lee, Se Hoon ^a,c   Kim, Dong Wan ^a,c   Im, Seock Ah ^a,c   Kim, Tae You ^a,c   Lee, Jong Seok ^b   Kim, Young Whan ^a   Heo, Dae Seog ^a,c   Bang, Yung Jue ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer; Pemetrexed

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTAMIC ACID DERIVATIVE; GUANINE; QUINAZOLINE DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CIGARETTE SMOKING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HUMAN; INDIGESTION; INFECTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DRUG COMBINATION; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 77952543145     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.013     Document Type: Article

References (30)

1. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
2. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
4. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
5. Hanauske A.R., Chen V., Paoletti P., Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001, 6:363-373.
6. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
7. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
8. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
9. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
10. Reni M., Pasetto L., Aprile G., Cordio S., Bonetto E., Dell'Oro S., et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006, 94:785-791.
11. Weiss G.J., Rosell R., Fossella F., Perry M., Stahel R., Barata F., et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18:453-460.
12. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007, 26:153-181.
13. Wang W., Marsh S., Cassidy J., McLeod H.L. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 2001, 61:5505-5510.
14. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66:431-438.
15. Chu E., Callender M.A., Farrell M.P., Schmitz J.C. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 2003, 52(Suppl. 1):S80-S89.
16. Gomez H.L., Santillana S.L., Vallejos C.S., Velarde R., Sanchez J., Wang X., et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006, 12:832-838.
17. Oguri T., Achiwa H., Sato S., Bessho Y., Takano Y., Miyazaki M., et al. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity. Mol Cancer Ther 2006, 5:1800-1806.
18. Kroep J.R., Loves W.J., van der Wilt C.L., Alvarez E., Talianidis I., Boven E., et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002, 1:371-376.
19. Bergman A.M., Giaccone G., van Moorsel C.J., Mauritz R., Noordhuis P., Pinedo H.M., et al. Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 2000, 36:1974-1983.
20. Wielinga P., Hooijberg J.H., Gunnarsdottir S., Kathmann I., Reid G., Zelcer N., et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005, 65:4425-4430.
21. Pratt S., Shepard R.L., Kandasamy R.A., Johnston P.A., Perry W., Dantzig A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005, 4:855-863.
22. Bergman A.M., Eijk P.P., Ruiz van Haperen V.W., Smid K., Veerman G., Hubeek I., et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65:9510-9516.
23. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64:3761-3766.
24. Goan Y.G., Zhou B., Hu E., Mi S., Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999, 59:4204-4207.
25. Belani C.P., Brodowicz T., Ciuleanu T., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2009, 27. CRA8000-
26. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
27. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
28. Scagliotti G., Monica V., Ceppi P., Righi L., Cambieri A., Volante M., et al. Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer. J Clin Oncol (Meeting Abstracts) 2009, 27. 7521
29. Gronberg B.H., Bremnes R.M., Flotten O., Amundsen T., Brunsvig P.F., Hjelde H.H., et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, JCO.2008.20.9114.
30. Sun J.M., Lee K.W., Kim J.H., Kim Y.J., Yoon H.I., Lee J.H., et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol 2009, 39:27-32.